Luisa Lina Villa1. 1. Ludwig Institute for Cancer Research - Hospital Alemão Oswaldo Cruz, São Paulo, SP, Brazil. llvilla@ludwig.org.br
Abstract
BACKGROUND: Human papillomaviruses (HPVs) play an obligatory role in cervical cancer development. Thus, immunization of women using a prophylactic vaccine against the most common high-oncogenic risk types (e.g., HPV 16 and 18) and HPV 6 and 11, which contribute to development of low-grade cervical lesions and cause most anogenital warts, represents a logical primary prevention strategy. PERSPECTIVES: At the time of licensure, Phase II/Phase III studies showed that administration of a quadrivalent HPV (types 6, 11, 16, 18) vaccine to young women (16 to 26 years) naïve to the vac- cine HPV types resulted in 100% efficacy against HPV 16- and 18-related precancerous cervical lesions, 100% efficacy against HPV 16- and 18-related high-grade vulvar/vaginal neoplasias, 95% efficacy against HPV 6, 11, 16, or 18-related cervical intraepithelial neoplasia/adenocarcinoma in situ, and 99% efficacy against HPV 6, 11, 16, or 18-related genital lesions. The quadrivalent HPV vaccine is highly immunogenic in adolescent males and females, and long-term follow up of young women did not detect evidence of waning immunity through 5 years. CONCLUSIONS: The quadrivalent vaccine is generally well tolerated. The efficacy and safety of the quadrivalent vaccine is continuing to be investigated in young men and mid-adult women. Nordic cancer registries are providing ongoing long-term pharmacovigilance.
BACKGROUND:Human papillomaviruses (HPVs) play an obligatory role in cervical cancer development. Thus, immunization of women using a prophylactic vaccine against the most common high-oncogenic risk types (e.g., HPV 16 and 18) and HPV 6 and 11, which contribute to development of low-grade cervical lesions and cause most anogenital warts, represents a logical primary prevention strategy. PERSPECTIVES: At the time of licensure, Phase II/Phase III studies showed that administration of a quadrivalent HPV (types 6, 11, 16, 18) vaccine to young women (16 to 26 years) naïve to the vac- cine HPV types resulted in 100% efficacy against HPV 16- and 18-related precancerous cervical lesions, 100% efficacy against HPV 16- and 18-related high-grade vulvar/vaginal neoplasias, 95% efficacy against HPV 6, 11, 16, or 18-related cervical intraepithelial neoplasia/adenocarcinoma in situ, and 99% efficacy against HPV 6, 11, 16, or 18-related genital lesions. The quadrivalent HPV vaccine is highly immunogenic in adolescent males and females, and long-term follow up of young women did not detect evidence of waning immunity through 5 years. CONCLUSIONS: The quadrivalent vaccine is generally well tolerated. The efficacy and safety of the quadrivalent vaccine is continuing to be investigated in young men and mid-adult women. Nordic cancer registries are providing ongoing long-term pharmacovigilance.
Authors: Mari Nygård; Alfred Saah; Christian Munk; Laufey Tryggvadottir; Espen Enerly; Maria Hortlund; Lara G Sigurdardottir; Scott Vuocolo; Susanne K Kjaer; Joakim Dillner Journal: Clin Vaccine Immunol Date: 2015-06-17
Authors: Nancy A Hessol; Elizabeth A Holly; Jimmy T Efird; Howard Minkoff; Kathleen M Weber; Teresa M Darragh; Robert D Burk; Howard D Strickler; Ruth M Greenblatt; Joel M Palefsky Journal: AIDS Date: 2013-07-17 Impact factor: 4.177
Authors: Elizabeth A Else; Ryan Swoyer; Yuhua Zhang; Frank J Taddeo; Janine T Bryan; John Lawson; Inez Van Hyfte; Christine C Roberts Journal: J Clin Microbiol Date: 2010-11-10 Impact factor: 5.948
Authors: S A Lippman; M C A Sucupira; H E Jones; C G Luppi; J Palefsky; J H H M van de Wijgert; R L S Oliveira; R S Diaz Journal: Int J STD AIDS Date: 2010-02 Impact factor: 1.359
Authors: James L Klosky; Heather L Gamble; Sheri L Spunt; Mary E Randolph; Daniel M Green; Melissa M Hudson Journal: Cancer Date: 2009-12-15 Impact factor: 6.860